1. In Vivo

Will 2021 Be A Turning Point For Pharnext?

 
• By Lucie Ellis-Taitt

After manufacturing issues disrupted a Phase III study for its lead pipeline candidate, Pharnext believes it is back on track with new management, a fresh clinical trial and strong guidance from regulators. New CEO David Horn Solomon has blockbuster expectations for the company’s rare disease drug. 

Rare flower
Pharnext moves rare disease drug closer to the market

David Horn Solomon joined Pharnext SA, a clinical-stage biopharmaceutical company that is developing new drug combinations based on big genomic data and artificial intelligence, in April 2020. He told In Vivo in an exclusive interview that he was attracted to Pharnext, a company that had been struggling with manufacturing challenges for its lead pipeline candidate, because of the clinical data it had produced for the rare disease Charcot-Marie-Tooth. There are no currently approved therapies for the disease.

“It was the data,” he said. “Charcot-Marie-Tooth is a neurological disorder, a demyelinating inherited peripheral neuropathy that begins in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.